BACKGROUND: Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD341 stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.
RESULTS:
Overall, 56 patients with TM (median age, 35 years; range, 13-52 years) and 13 with TI (median age, 44 years; range, 27-67 years) were evaluated. Annual red blood cell (RBC) transfusion requirements ranged from 10 to 65 units in all patients except four nontransfused cases. A significant increase in peripheral circulating stem cells was observed in patients, in comparison with healthy controls. Nontransfused patients showed the mean highest levels of stem cells (CD34, 32.5 6 14.8/lL; BFU-E, 41.3 6 22.8/mL; CFU-GM, 19.6 6 5.6/ mL; CFU-GEMM, 9.0 6 6.1/mL). CD341 cell count was 6.9 6 4.5/lL in TM (p = 0.014) and 11.8 6 14.8/lL (p 5 0.051) in TI. Furthermore, only in patients with TI was a significant increase in CFU-GEMM (3.0 6 4.8 vs. 0.75 6 2.05/mL, p 5 0.0001) observed. At multivariate analysis, peripheral circulating CD341 stem cells did not correlate with age, sex, smoking habit, number of RBCs units transfused, Hb levels, iron chelation therapy, history of splenectomy, and hypothyroidism. CONCLUSION: Circulating peripheral CD34 1 stem cells are increased in b-thalassemia, in particular in nontransfused patients, compared to healthy controls. b -Thalassemias are determined by a reduced or absent b-globin synthesis, ineffective erythropoiesis, and compensatory erythroid hyperplasia. b-Thalassemia is characterized by a wide range of clinical severity, from high transfusion dependency (in bthalassemia major [TM]) to partially less severe anemia (in b-thalassemia intermedia [TI]). TM is treated with regular blood transfusion and iron chelation therapy since infancy, while patients with TI are usually transfusion independent and their clinical phenotype is intermediate between TM and asymptomatic heterozygous. 1 Little is known about the effects of blood transfusions on circulating hemopoietic progenitors in b-thalassemia patients. Circulating myeloid stem cells (CFU-c) in the peripheral blood of children with TM have been assessed in the early 1980s with culture techniques. 2 CFU-c were actively proliferating and higher in number in splenectomized patients than in controls; their amount was positively related with the time elapsed since the last transfusion. Mean higher hemoglobin (Hb) levels were associated with a marked reduction in the number of CFU-c. Authors of this seminal work hypothesized that an ABBREVIATIONS: TI 5 thalassemia intermedia; TM 5 thalassemia major. increased hematopoiesis, shown by elevated circulating hematopoietic progenitor cells and serum erythropoietin levels, could mirror a still active regulation of erythropoiesis in patients with TM.
In physiologic conditions, circulating hemopoietic progenitors may be used in peripheral tissues during prolonged endurance exercise. 3, 4 Circulating hemopoietic progenitors have been also reported to increase in healthy subjects after acute exercise and during tissue repair. 5, 6 Circulating erythroid-burst-forming units (BFU-E) have been determined in patients with b-TM, 7 more recently in the context of gene therapy studies. 8 A significant increase of circulating erythroid progenitor cells (three to five times more than normal) has been reported in thalassemia, with a linear relationship between the number of BFU-E and CFU. 9 The absolute number of all hematopoietic peripheral progenitors was very high in splenectomized patients with TM undergoing iron chelation, when compared to controls. 10 In the current preliminary study we aimed to prospectively evaluate the role of peripheral circulating CD341 stem cells (PBSC CD341) and erythroid precursors as independent markers of appropriate hematopoietic balance in patients with TM and TI.
MATERIALS AND METHODS
A prospective study on 69 thalassemia patients was performed from January 2013 to January 2014. All patients with a diagnosis of TM and TI, undergoing regular followup visits in the past 2 years were considered eligible. For patients under regular transfusion therapy, all those with a stable pretransfusional Hb level of more than 9 g/dL in the last control were included. 11 Patients with human immunodeficiency virus infection were excluded. Thirty age-and sex frequency-matched healthy volunteer blood donors were also studied as controls. Demographic and clinical data were retrieved from patient charts of all the enrolled subjects and recorded in a dedicated database.
Peripheral blood samples from patients with thalassemia were collected in heparinized tubes, at least 15 days after the last transfusion. Healthy volunteers did not take any medication in the last 10 days before blood donation. PBSC CD341 count was assayed according to international guidelines. 12 For the determination of CD341 cells, monoclonal antibodies CD45-FITC and CD34-PE and isotype controls (immunoglobulin G1 [IgG1]-FITC/IgG1-PE) were incubated with 100 lL of EDTA-anticoagulated blood (BD stem cell enumeration kit, Becton Dickinson, Franklin Lakes, NJ). For the CD341 cell quantification by flow cytometry, a minimum of 100 CD341 and 10 5 CD451 events were analyzed. Colony-forming cells (colony-forming unit-granulocyte/macrophage [CFU-GM], BFU-E, colony-forming unit-granulocyte, erythrocyte, macro-phage, megakaryocyte [CFU-GEMM]) determinations were performed according to a standardized method (Methocult H 4434, Stem Cell Technologies, Inc., Vancouver, British Columbia, Canada). 13 All variables were analyzed using descriptive statistics. Comparison between groups was made using analysis of variance models; chi-square test was applied for categorical variables. Spearman's rank correlation coefficient was applied as nonparametric measure of statistical dependence between two variables. The Wilcoxon signedrank test was adopted as nonparametric test when comparing two samples without normal distribution. All p values are two-sided with the level of significance set at 0.05. Analysis was carried out using computer software (SPSS 15.0, SPSS, Inc., Chicago, IL). The study was approved by the internal review board of "Giovanni Paolo II" Hospital, Sciacca, and all participants signed informed consent before recruitment.
RESULTS
Overall, 56 Caucasian patients with TM (median age, 35 years; range, 13-52 years) and 13 with TI (median age, 42 years; range, 27-67 years) were evaluated. Baseline data are reported in Table 1 . Twenty-eight patients with TM and six patients with TI were females. Body mass index was 21.5 in patients with TM (range, 15.7-27.3; SD, 3.1) and 21.4 in patients with TI (range, 14.7-33.5; SD, 4.6). Thirty-one patients with TM and all the patients with TI had a history of splenectomy. All healthy volunteer blood donors were not splenectomized; physical examination did not show hepatosplenomegaly. Nine patients with TM and one patient with TI had hypothyroidism. Fifty-five patients with TM and 10 patients with TI received iron chelation (mainly with deferasirox [n 5 23] and deferoxamine [n 5 18]). Mean Hb levels were 9.5 g/dL in patients with TM (range, 7.4-11 g/dL) and 8.9 (range, 8-9.8) g/dL in patients with TI. Annual RBC transfusion requirements ranged from 10 to 65 units in patients with TM (mean 6 SD, 34.5 6 10.8) and from 14 to (Fig. 1 ) were 6.9 6 4.5/lL in patients with TM and 11.8 6 14.8/lL in patients with TI, significantly higher than mean CD341 cells count of healthy volunteer blood donors (3.5 6 2.9/lL p5 0.014 and p 5 0.051, respectively).
DISCUSSION
Regular blood transfusions are the mainstay of treatment in patients with thalassemia and they effectively supply normal RBCs, partially inhibiting marrow expansion. 12 In the analyzed cohort of Caucasian patients with thalassemia, the highest count of CD341 circulating cells is observed in nontransfused patients, with an increased hematopoietic stress and compensatory marrow hyperplasia (TI, nontransfused). In addition to total CD341 progenitors, we also determined the levels of different hematopoietic progenitor types (BFU-E, CFU-GM, and CFU-GEMM), showing a direct correlation with PBSC CD341 count in nontransfused patients with thalassemia. Peripheral progenitors have been determined in patients with TM treated with iron chelators 10 and results were particularly high under deferasirox. In the current report iron chelation does not correlate with PBSC CD341count.
The potential role of circulating progenitors for autologous stem cell transplantation and gene therapy has been widely investigated. 14 Yannaki and colleagues 14 found that baseline PBSC CD341 count in patients with TM was slightly higher than in normal controls. TM, characterized by an expansion of marrow cellularity, also determines an increased release of hematopoietic precursors in peripheral blood. 15 We have observed a nonsignificant association between splenectomy and PBSC CD341count, thus confirming previous data. 15 Our preliminary findings suggest that the determination of PBSC CD341 in patients with b-thalassemia may be a useful additional marker for the evaluation of clinical response to transfusion; however, further prospective studies are needed to draw clinical recommendations. The assessment of new markers is desirable to improve the personalized transfusion care of thalassemia.
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